Exploring the Use of Multimodal Real-World Data in Precision Medicine and Its Benefits for Treatment Personalization

Multimodal real-world data means combining different kinds of patient information from many sources. This includes electronic health records (EHRs), genetic and molecular tests, lab results, imaging scans, and even data reported by patients themselves. Instead of using only one type of data, multimodal data gives a wider view of a patient’s condition by linking clinical facts with genetic and behavior details.
For example, usual cancer care might only look at a tissue biopsy or symptoms. But multimodal data connects genetic sequencing results, protein analysis, and patient history to make a fuller picture of the disease. Using these data types together helps doctors make better diagnoses, find new treatment targets, and pick the right clinical trials for patients.

Role of Multimodal Data in Precision Medicine

Precision medicine depends on carefully using different data to stop using the “one-size-fits-all” method. When real-world clinical data is combined with molecular data like genomic and transcriptomic profiles, doctors can tailor treatments based on unique tumor mutations or an individual’s genes.
A clear example in the U.S. is in cancer care. Tools like the Tempus AI platform help medical centers give better cancer treatment. About 65% of academic medical centers and more than half of U.S. cancer doctors use platforms that bring together multimodal data to make smarter treatment choices. Tempus has over 8 million anonymous patient records used to find new treatment targets and close gaps in care.
At Ochsner Health in New Orleans, Dr. Marc Matrana showed that using RNA sequencing with DNA tests found lung cancer markers that regular DNA tests missed. This discovery led to new treatment options. It shows how multimodal data can increase care options that were not available before.
Also, drug companies use this data a lot. AstraZeneca, for example, applies multimodal real-world data in its Phase 3 cancer trials to better predict how patients respond to new treatments. This helps make drug development more focused, lowers trial failures, and improves chances of giving patients effective medicines.

Benefits for Treatment Personalization

• Improved Diagnosis: Combining clinical symptoms with molecular data helps catch rare and subtle disease markers early. This is very important for complex illnesses like cancer or Alzheimer’s disease where early finding helps results.
• Better Treatment Matching: Platforms with multimodal data match patients to personalized treatments based on their genes and tumor biology. For example, Tempus’ xT platform uses combined molecular and clinical data to increase therapy choices for cancer patients.
• Clinical Trial Enrollment: AI analyzing multimodal data finds patients suitable for certain clinical trials. This speeds up enrollment and raises success rates. More than 30,000 patients in Tempus’ network have been identified for potential trial participation this way.
• Reduced Side Effects: Precision medicine also picks medicines with fewer side effects. In mental health clinics, pharmacogenomics—choosing medication based on genetic data—has lowered unwanted reactions. Dr. Brian Forsythe calls this a big step forward in personalized medicine.
• Early Detection of Cognitive Disorders: AI combined with electronic health records helps spot mild cognitive impairment (MCI), an early sign of Alzheimer’s often missed in regular care. AI tools help providers find at-risk patients between 6% and 15% of the time those cases are missed now.

All in all, multimodal data helps move healthcare from standard treatments to plans made just for each patient’s specific condition.

The Scale of Multimodal Data Use in the United States

Many U.S. healthcare centers use multimodal real-world data approaches. About 65% of academic medical centers use platforms like Tempus for cancer care. Also, over half of U.S. cancer doctors use these tools to get detailed genetic sequencing, match clinical trials, and join research.
Drug companies also work widely with these platforms. Ninety-five percent of the top 20 cancer drug firms team up to use genomic and clinical data. These partnerships support more than 200 projects aimed at making new drugs and doing clinical research.
The amount of data is huge. For example, Tempus handles over 300 petabytes of data from many sources like clinical records and molecular profiles. This big data storage is key for AI systems to find useful insights for personalized care.

AI and Workflow Automation: Streamlining Healthcare Front-Office Operations

Most people think of AI for clinical decisions and data analysis. But AI is also growing in automating front-office work in medical practices. For healthcare administrators, owners, and IT managers, AI tools that manage calls and admin tasks can reduce work and improve patient contact.
AI tools like Simbo AI handle phone calls by automating responses and booking appointments. This cuts call wait times, lowers no-shows by sending reminders, and frees staff from repeating tasks like checking insurance or registering patients. Studies show AI systems linked to electronic health records automate everyday front-office work, making offices run smoother and patients happier.
Also, some platforms used for multimodal data are changed to manage workflows. For instance, AI patient screening tools can prequalify patients for clinical trials while managing scheduling. This lets clinical staff focus more on direct patient care. These tools have doubled clinical trial screening speeds. ConcertAI’s CARA system signed up 120 patients in 25 hours compared to 58 patients in 40 hours with old methods.
Plus, AI health apps like Tempus’ Olivia help patients and caregivers manage health data. By improving communication between patients and doctors, these apps help patients follow treatment and keep care steady.

Data Privacy and Compliance Considerations

Handling multimodal real-world data means patient privacy is very important. Health systems use de-identified or synthetic data that looks like real patient data but doesn’t show personal information. This approach balances using data well with following laws like HIPAA. It keeps AI model building and research safe for patient privacy.
Healthcare groups, tech companies, and regulators work together to build safe ways to combine different data types. These efforts make sure patient data is treated carefully while moving precision medicine ahead.

Importance for U.S. Medical Practices

For medical practices in the U.S., using multimodal real-world data technology offers access to better clinical information and strong support in care management. Cancer centers and academic hospitals benefit a lot from using these data-driven precision platforms in patient care. This helps doctors offer personalized care based on full data instead of just usual protocols.
Medical administrators and IT managers can work on adding systems that mix clinical data, molecular tests, and AI studies while making sure workflows improve with automation. These changes lead to better use of resources, less admin work, and quicker patient contact.
Since nearly two-thirds of academic medical centers in the U.S. already use these platforms, joining this trend helps practices stay competitive and effective. Practices can also improve chances to join research by finding the right patients for clinical trials, which supports better treatments and possible extra income.